Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Mazoyer (2005)
Genomic rearrangements in the BRCA1 and BRCA2 genesHuman Mutation, 25
S. Antonarakis (1998)
Recommendations for a nomenclature system for human gene mutationsHuman Mutation, 11
R. Scully, Junjie Chen, A. Plug, Yonghong Xiao, D. Weaver, J. Feunteun, T. Ashley, D. Livingston (1997)
Association of BRCA1 with Rad51 in Mitotic and Meiotic CellsCell, 88
Elmasry (2007)
115
J. Dunnen, S. Antonarakis (2000)
Mutation nomenclature extensions and suggestions to describe complex mutations: A discussionHuman Mutation, 15
Wooster (1995)
789Nature, 378
Deborah Thompson, D. Easton (2001)
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.American journal of human genetics, 68 2
Deborah Thompson, D. Easton (2002)
Variation in BRCA1 cancer risks by mutation position.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 11 4
F. Casilli, I. Tournier, O. Sinilnikova, F. Coulet, F. Soubrier, C. Houdayer, A. Hardouin, P. Berthet, H. Sobol, V. Bourdon, D. Muller, J. Fricker, C. Capoulade-Métay, A. Chompret, C. Noguès, S. Mazoyer, P. Chappuis, P. Maillet, C. Philippe, A. Lortholary, P. Gesta, S. Bézieau, C. Toulas, L. Gladieff, C. Maugard, D. Provencher, C. Dugast, C. Delvincourt, T. Nguyen, L. Faivre, V. Bonadona, T. Frebourg, R. Lidereau, D. Stoppa-Lyonnet, M. Tosi (2006)
The contribution of germline rearrangements to the spectrum of BRCA2 mutationsJournal of Medical Genetics, 43
A. Antoniou, P. Pharoah, G. McMullan, N. Day, Michael Stratton, J. Peto, B. Ponder, D. Easton (2002)
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genesBritish Journal of Cancer, 86
S. Gayther, P. Russell, P. Harrington, A. Antoniou, D. Easton, B. Ponder (1999)
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.American journal of human genetics, 65 4
Hogervorst (2003)
1449Cancer Res, 63
R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs, Gos Michlem, R. Barfoot, R. Hamoudi, Sandeep Patel, C. Rice, P. Biggs, Yasmin Hashim, Amanda Smith, F. Connor, A. Arason, J. Gudmundsson, D. Ficenec, D. Kelsell, D. Ford, P. Tonin, D. Bishop, N. Spurr, B. Ponder, R. Eeles, J. Peto, P. Devilee, C. Cornelisse, H. Lynch, S. Narod, G. Lenoir, V. Egilsson, Rosa Barkadottir, D. Easton, D. Bentley, P. Futreal, A. Ashworth, M. Stratton (1996)
Identification of the breast cancer susceptibility gene BRCA2Nature, 379
B. Werness, S. Ramus, R. Dicioccio, A. Whittemore, Kim Garlinghouse-Jones, I. Oakley-Girvan, Y. Tsukada, P. Harrington, S. Gayther, B. Ponder, S. Piver (2004)
Histopathology, FIGO Stage, and BRCA Mutation Status of Ovarian Cancers from the Gilda Radner Familial Ovarian Cancer RegistryInternational Journal of Gynecological Pathology, 23
Laure Perrin-Vidoz, O. Sinilnikova, D. Stoppa-Lyonnet, G. Lenoir, S. Mazoyer (2002)
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons.Human molecular genetics, 11 23
A. Whittemore, R. Balise, P. Pharoah, R. Dicioccio, I. Oakley-Girvan, S. Ramus, M. Daly, M. Usinowicz, Kim Garlinghouse-Jones, B. Ponder, S. Buys, R. Senie, I. Andrulis, E. John, J. Hopper, M. Piver (2004)
Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutationsBritish Journal of Cancer, 91
S. Gayther, W. Warren, S. Mazoyer, P. Russell, P. Harrington, M. Chiano, S. Seal, R. Hamoudi, E. Rensburg, A. Dunning, R. Love, G. Evans, D. Easton, D. Clayton, M. Stratton, B. Ponder (1995)
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlationNature Genetics, 11
Anne Petrij-Bosch, T. Peelen, M. Vliet, R. Eijk, R. Olmer, M. Drüsedau, F. Hogervorst, S. Hageman, P. Arts, M. Ligtenberg, H. Meijers-Heijboer, J. Klijn, H. Vasen, C. Cornelisse, L. Veer, E. Bakker, G. Ommen, P. Devilee (1997)
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patientsNature Genetics, 17
J. Stratton, P. Pharoah, Steven Smith, D. Easton, B. Ponder (1998)
A systematic review and meta‐analysis of family history and risk of ovarian cancerBJOG: An International Journal of Obstetrics & Gynaecology, 105
A. Antoniou, P. Pharoah, S. Narod, H. Risch, J. Eyfjord, J. Hopper, N. Loman, Hampus Olsson, O. Johannsson, Å. Borg, B. Pasini, P. Radice, S. Manoukian, D. Eccles, N. Tang, E. Oláh, H. Anton-Culver, E. Warner, J. Lubiński, J. Gronwald, B. Górski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjäkoski, O. Kallioniemi, Deborah Thompson, Chris Evans, J. Peto, F. Lalloo, D. Evans, D. Easton (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.American journal of human genetics, 72 5
Puget (1997)
828Cancer Res, 57
A. Woodward, T. Davis, A. Silva, Judy Kirk, Jennifer Leary (2005)
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected familiesJournal of Medical Genetics, 42
Y. Miki, J. Swensen, D. Shattuck-Eidens, P. Futreal, K. Harshman, S. Tavtigian, Qingyun Liu, C. Cochran, L. Bennett, W. Ding, R. Bell, J. Rosenthal, C. Hussey, Thanh Tran, M. Mcclure, C. Frye, T. Hattier, R. Phelps, A. Haugen-Strano, H. Katcher, Kazuko Yakumo, Z. Gholami, Daniel Shaffer, S. Stone, Steven Bayer, Christian Wray, R. Bogden, P. Dayananth, J. Ward, P. Tonin, S. Narod, Pamela Bristow, F. Norris, L. Helvering, P. Morrison, P. Rosteck, Mei Lai, J. Barrett, C. Lewis, S. Neuhausen, L. Cannon-Albright, D. Goldgar, R. Wiseman, A. Kamb, M. Skolnick (1994)
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.Science, 266 5182
G. Lathrop, J. Lalouel, C. Julier, J. Ott (1984)
Strategies for multilocus linkage analysis in humans.Proceedings of the National Academy of Sciences of the United States of America, 81 11
T. Walsh, S. Casadei, Kathryn Coats, E. Swisher, S. Stray, Jake Higgins, Kevin Roach, Jessica Mandell, Ming Lee, S. Ciernikova, L. Foretova, P. Souček, M. King (2006)
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.JAMA, 295 12
N. Puget, O. Sinilnikova, D. Stoppa-Lyonnet, C. Audoynaud, S. Pagès, H. Lynch, D. Goldgar, G. Lenoir, S. Mazoyer (1999)
An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?American journal of human genetics, 64 1
S. Mazoyer, J. Leary, J. Kirk, E. Fleischmann, T. Wagner, K. Claes, L. Messiaen, W. Foulkes, M. Desrochers, J. Simard, C. Phelan, E. Kwan, S. Narod, P. Vahteristo, H. Nevanlinna, X. Durando, Y. Bignon, J. Peyrat, C. Bonnardel, O. Sinilnikova, N. Puget, G. Lenoir, C. Audoynaud, D. Goldgar, C. Maugard, V. Caux, S. Gad, D. Stoppa-Lyonnet, C. Noguès, R. Lidereau, C. Machavoine, B. Paillerets, B. Kuschel, B. Betz, D. Niederacher, M. Beckmann, U. Hamann, S. Gayther, B. Ponder, M. Robinson, G. Taylor, T. Bishop, A. Catteau, E. Solomon, B. Cohen, M. Steel, N. Collins, M. Stratton, M. Looij, E. Oláh, N. Miller, D. Barton, R. Sverdlov, E. Friedman, P. Radice, M. Montagna, E. Sensi, M. Caligo, R. Eijk, P. Devilee, R. Luijt, K. Heimdal, P. Møller, Å. Borg, O. Díez, J. Cortés, M. Doménech, M. Baiget, A. Osorio, J. Benítez, P. Maillet, A. Sappino, H. Özdağ, T. Ozcelik, M. Ozturk, E. Rohlfs, J. Boyd, D. McDermott, K. Offit, Meredith Unger, K. Nathanson, B. Weber, T. Sellers, E. Hampton, F. Couch, S. Neuhausen (2000)
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group.American journal of human genetics, 67 1
K Elmasry, SA Gayther (2007)
Cancer of the ovary
P. Pharoah, A. Antoniou, M. Bobrow, R. Zimmern, D. Easton, B. Ponder (2002)
Polygenic susceptibility to breast cancer and implications for preventionNature Genetics, 31
A. Antoniou, S. Gayther, J. Stratton, B. Ponder, D. Easton (2000)
Risk models for familial ovarian and breast cancerGenetic Epidemiology, 18
N. Puget, N. Puget, D. Stoppa-Lyonnet, O. Sinilnikova, O. Sinilnikova, S. Pagès, H. Lynch, G. Lenoir, G. Lenoir, S. Mazoyer, S. Mazoyer (1999)
Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions.Cancer research, 59 2
M. Piver, Y. Tsukada, B. Werness, R. Dicioccio, A. Whittemore, B. Ponder (2000)
Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: a study by the Gilda Radner Familial Ovarian Cancer Registry.Gynecologic oncology, 78 2
D. Ford, D. Easton, Michael Stratton, S. Narod, D. Goldgar, P. Devilee, D. Bishop, B. Weber, G. Lenoir, J. Chang-Claude, H. Sobol, M. Teare, J. Struewing, A. Arason, S. Scherneck, J. Peto, T. Rebbeck, P. Tonin, S. Neuhausen, R. Barkardottir, J. Eyfjord, H. Lynch, B. Ponder, S. Gayther, J. Birch, A. Lindblom, D. Stoppa-Lyonnet, Y. Bignon, Å. Borg, U. Hamann, N. Haites, Rodney Scott, C. Maugard, H. Vasen, S. Seitz, L. Cannon-Albright, A. Schofield, M. Zelada-Hedman (1998)
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.American journal of human genetics, 62 3
Thompson (2002)
329Cancer Epidemiol Biomarkers Prev, 11
M. Ware, D. DeSilva, O. Sinilnikova, D. Stoppa-Lyonnet, S. Tavtigian, S. Mazoyer (2006)
Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene?Oncogene, 25
F. Hogervorst, P. Nederlof, J. Gille, C. Mcelgunn, Maartje Grippeling, Roelof Pruntel, Rein Regnerus, Tibor Welsem, R. Spaendonk, F. Menko, I. Kluijt, C. Dommering, S. Verhoef, J. Schouten, L. Veer, G. Pals (2003)
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.Cancer research, 63 7
N. Puget, N. Puget, D. Torchard, O. Serova-Sinilnikova, O. Serova-Sinilnikova, H. Lynch, J. Feunteun, G. Lenoir, G. Lenoir, S. Mazoyer, S. Mazoyer (1997)
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17.Cancer research, 57 5
Puget (1999)
455Cancer Res, 59
D. Schorderet, L. Tiab, M. Gaillard, B. Lorenz, G. Klainguti, J. Kerrison, E. Traboulsi, F. Munier (2007)
Novel mutations in FRMD7 in X‐linked congenital nystagmusHuman Mutation, 28
I. Tournier, B. Paillerets, H. Sobol, D. Stoppa-Lyonnet, R. Lidereau, M. Barrois, S. Mazoyer, F. Coulet, A. Hardouin, A. Chompret, A. Lortholary, P. Chappuis, V. Bourdon, V. Bonadona, C. Maugard, Brigitte Gilbert, C. Noguès, T. Frebourg, M. Tosi (2004)
Significant Contribution of Germline BRCA2 Rearrangements in Male Breast Cancer FamiliesCancer Research, 64
P. Bork, Kay Hofmann, P. Bucher, A. Neuwald, S. Altschul, E. Koonin (1997)
A superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteinsThe FASEB Journal, 11
L. Mcgowan (1989)
Epidemiology of ovarian cancer.Oncology, 3 1
S. Ramus, P. Harrington, C. Pye, S. Peock, M. Cook, M. Cox, I. Jacobs, R. Dicioccio, A. Whittemore, M. Piver, D. Easton, B. Ponder, P. Pharoah, S. Gayther (2007)
Screening for the BRCA1‐ins6kbEx13 mutation: potential for misdiagnosisHuman Mutation, 28
M. Montagna, M. Palma, C. Menin, S. Agata, A. Nicolo, L. Chieco‐Bianchi, E. D'andrea (2003)
Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families.Human molecular genetics, 12 9
S. Gayther, J. Mangion, P. Russell, S. Seal, R. Barfoot, B. Ponder, M. Stratton, D. Easton (1997)
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 geneNature Genetics, 15
A total of 283 epithelial ovarian cancer families from the United Kingdom (UK) and the United States (US) were screened for coding sequence changes and large genomic alterations (rearrangements and deletions) in the BRCA1 and BRCA2 genes. Deleterious BRCA1 mutations were identified in 104 families (37%) and BRCA2 mutations in 25 families (9%). Of the 104 BRCA1 mutations, 12 were large genomic alterations; thus this type of change represented 12% of all BRCA1 mutations. Six families carried a previously described exon 13 duplication, known to be a UK founder mutation. The remaining six BRCA1 genomic alterations were previously unreported and comprised five deletions and an amplification of exon 15. One of the 25 BRCA2 mutations identified was a large genomic deletion of exons 19–20. The prevalence of BRCA1/2 mutations correlated with the extent of ovarian and breast cancer in families. Of 37 families containing more than two ovarian cancer cases and at least one breast cancer case with diagnosis at less than 60 years of age, 30 (81%) had a BRCA1/2 mutation. The mutation prevalence was appreciably less in families without breast cancer; mutations were found in only 38 out of 141 families (27%) containing two ovarian cancer cases only, and in 37 out of 59 families (63%) containing three or more ovarian cancer cases. These data indicate that BRCA1 and BRCA2 are the major susceptibility genes for ovarian cancer but that other susceptibility genes may exist. Finally, it is likely that these data will be of clinical importance for individuals in families with a history of epithelial ovarian cancer, in providing accurate estimates of their disease risks. Hum Mutat 28(12), 1207–1215, 2007. © 2007 Wiley‐Liss, Inc.
Human Mutation – Wiley
Published: Dec 1, 2007
Keywords: ovarian cancer; breast cancer; family history; mutation screening; BRCA1; BRCA2
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.